F
Francesco Micheletto
Researcher at University of Padua
Publications - 10
Citations - 1043
Francesco Micheletto is an academic researcher from University of Padua. The author has contributed to research in topics: Insulin & Type 2 diabetes. The author has an hindex of 9, co-authored 10 publications receiving 847 citations. Previous affiliations of Francesco Micheletto include University of Virginia.
Papers
More filters
Journal ArticleDOI
The UVA/PADOVA Type 1 Diabetes Simulator New Features
Chiara Dalla Man,Francesco Micheletto,Dayu Lv,Marc D. Breton,Boris Kovatchev,Claudio Cobelli +5 more
TL;DR: A new version of the UVA/PADOVA Type 1 Diabetes Simulator, which was submitted to FDA in 2013, provides a more reliable framework for in silico trials, for testing glucose sensors and insulin augmented pump prediction methods, and for closed-loop single/dual hormone controller design, testing, and validation.
Journal ArticleDOI
Contribution of Endogenous Glucagon-Like Peptide 1 to Glucose Metabolism After Roux-en-Y Gastric Bypass
Meera Shah,Jennie H. Law,Francesco Micheletto,Matheni Sathananthan,Chiara Dalla Man,Claudio Cobelli,Robert A. Rizza,Michael Camilleri,Alan R. Zinsmeister,Adrian Vella +9 more
TL;DR: Exendin-9,39 is used to examine glucose metabolism, islet hormone secretion, and gastrointestinal transit in subjects after RYGB and in matched control subjects to indicate that endogenous GLP-1 has effects on glucose metabolism and on gastrointestinal motility years after RyGB.
Journal ArticleDOI
Common genetic variation in GLP1R and insulin secretion in response to exogenous GLP-1 in nondiabetic subjects: a pilot study.
Airani Sathananthan,Chiara Dalla Man,Francesco Micheletto,Alan R. Zinsmeister,Michael Camilleri,Paula D. Giesler,Jeanette Laugen,Gianna Toffolo,Robert A. Rizza,Claudio Cobelli,Adrian Vella +10 more
TL;DR: Variation in GLP1R may alter insulin secretion in response to exogenous GLP-1 in nondiabetic subjects and future studies will determine whether such variation accounts for interindividual differences in responses to GLP–1–based therapy.
Journal ArticleDOI
The effect of DPP-4 inhibition with sitagliptin on incretin secretion and on fasting and postprandial glucose turnover in subjects with impaired fasting glucose.
Gerlies Bock,Chiara Dalla Man,Francesco Micheletto,Rita Basu,Paula D. Giesler,Jeanette Laugen,Carolyn F. Deacon,Jens J. Holst,Gianna Toffolo,Claudio Cobelli,Robert A. Rizza,Adrian Vella +11 more
TL;DR: Dipeptidyl peptidase‐4 (DPP‐4) inhibitors raise incretin hormone concentrations enabling an examination of their effects on glucose turnover in IFG.
Journal ArticleDOI
A Model of GLP-1 Action on Insulin Secretion in Nondiabetic Subjects
Chiara Dalla Man,Francesco Micheletto,Airani Sathananthan,Robert A. Rizza,Adrian Vella,Claudio Cobelli +5 more
TL;DR: A mechanistic model enabling quantitation of pancreatic response to GLP-1 has never been developed, and the model that best fit C-peptide data assumes that above-basal insulin secretion depends linearly on GLp-1 concentration and its rate of change.